Clinical Trial Results:
A 24-week open-label, multicenter, follow-up and extension study to CACZ885H2251, to assess safety, tolerability and efficacy of canakinumab (ACZ885) in patients with gout who are given canakinumab at the time of gout flare.
Summary
|
|
EudraCT number |
2009-012316-40 |
Trial protocol |
GB SK BE ES PT CZ HU DE |
Global completion date |
04 Aug 2010
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
16 Sep 2016
|
First version publication date |
16 Sep 2016
|
Other versions |
|
Summary report(s) |
CACZ885H2251E1.CTR.19Aug2016 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.